Table 5 Association of T2DM and antidiabetic medications with high-risk, regional metastases and distant metastases of prostate cancer 1

 no DM

Ref

Ref

Ref

 T2DM

0.93

(0.87–1.00)

0.9

(0.78–1.04)

0.91

(0.82–1.00)

 no DM

Ref

Ref

Ref

  < 1

1.28

(0.97–1.68)

0.76

(0.43–1.35)

1.33

(0.95–1.87)

 1 - < 5

0.99

(0.85–1.14)

0.87

(0.66–1.15)

0.8

(0.65–0.97)

 5 - < 10

0.95

(0.83–1.08)

0.84

(0.64–1.09)

0.87

(0.73–1.04)

 10 - < 20

0.9

(0.80–1.02)

0.97

(0.77–1.22)

0.89

(0.76–1.04)

 20

0.77

(0.63–0.94)

0.96

(0.69–1.35)

1.06

(0.84–1.32)

 no DM

Ref

Ref

Ref

 0.5 - < 3

0.77

(0.60–0.98)

0.52

(0.31–0.88)

0.9

(0.68–1.19)

 3 - < 5

0.85

(0.63–1.16)

0.97

(0.57–1.65)

0.83

(0.58–1.20)

 5

0.86

(0.72–1.01)

0.88

(0.64–1.21)

0.96

(0.78–1.18)

 Missing

 no DM

Ref

Ref

Ref

 0.5 - < 3

0.89

(0.77–1.03)

0.87

(0.66–1.15)

0.84

(0.69–1.02)

 3 - < 5

0.96

(0.77–1.20)

1.23

(0.82–1.83)

0.89

(0.67–1.20)

 5

1.19

(0.94–1.50)

0.96

(0.61–1.52)

1.25

(0.93–1.68)

 Missing

 no DM

Ref

Ref

Ref

 0.5 - < 3

0.97

(0.86–1.09)

0.89

(0.71–1.12)

0.86

(0.74–1.00)

 3 - < 5

0.85

(0.72–1.02)

1

(0.73–1.38)

0.81

(0.64–1.02)

 5

0.97

(0.76–1.23)

1.44

(0.97–2.15)

0.87

(0.65–1.17)

 Missing

 no DM

Ref

Ref

Ref

 0.5 - < 3

0.7

(0.55–0.88)

0.89

(0.58–1.36)

0.83

(0.62–1.09)

 3 - < 5

0.85

(0.63–1.15)

0.95

(0.53–1.70)

0.65

(0.43–0.98)

 5

0.74

(0.57–0.96)

0.81

(0.51–1.28)

1.07

(0.81–1.42)

 Missing